ANTHEM
Anthem Biosciences Limited (NSE: Anthem) Q4 FY26: Revenue Up 26%, PAT Surges 130%
Anthem Biosciences Limited (NSE: ANTHEM) announced its Q4 FY26 results with a 26% YoY revenue growth and a 129.8% surge in PAT.
Anthem Biosciences Limited (NSE: ANTHEM) announced its audited consolidated financial results for the quarter and year ended March 31, 2026, showcasing robust growth. For the quarter, consolidated revenue from operations stood at ₹6,109 Mn, marking a 26.4% year-on-year increase. The company’s EBITDA for the quarter was ₹3,184 Mn, with margins at 48.1%, reflecting strong operational efficiency. Notably, the Profit After Tax (PAT) for Q4 FY26 was ₹1,898 Mn, a significant 129.8% rise compared to the same period last year.
Full Year Financial Highlights
For FY26, Anthem Biosciences Limited reported consolidated revenue from operations of ₹21,243 Mn, a 15.2% increase from the previous year. The company’s EBITDA for the full year was ₹9,896 Mn, with margins at 43.4%. The PAT for FY26 was ₹5,918 Mn, showing a 31.1% growth year-on-year. The company’s commitment to prudent cost management and focus on long-term value creation has enabled it to expand profitability margins while delivering this revenue growth.
Looking Ahead
Commenting on the results, Ajay Bhardwaj, Chairman, MD, and CEO of Anthem Biosciences Limited, said, “We ended the financial year 2025–26 on a strong note, with our highest revenue quarter ever in Q4FY26. Anthem’s commitment to prudent cost management and focus on long-term value creation has enabled us to expand profitability margins while delivering this revenue growth. The Company continues to maintain a healthy financial position and remains committed to delivering sustainable growth across all business segments. As we step into financial year 2026–27, our priorities remain clear: to build one of the most agile, science-led, and future-ready CRDMO platforms in the world.”
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Anthem Biosciences Limited
Anthem Biosciences Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.
Anthem rises 14.7% over three months, with buying pressure holding steady. The PEG stands at 25.44 — severely stretched. Any earnings miss could trigger a sharp de-rating. Margins at 24.2% are impressive but need to be sustained — any compression would be a red flag. Buyers show up with 1.7x the volume of sellers. Moreover, they dominated on 19 of recent sessions versus 11 for sellers — a healthy accumulation pattern. The stock rises 14.7% in three months on 14.4% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Anthem Biosciences Limited.
ANTHEM
Anthem Biosciences Limited (NSE: Anthem) Q2 & H1 FY27 Results: Robust Performance and Margin Expansion
Anthem Biosciences Limited (NSE: ANTHEM) reports strong Q2 & H1 FY27 results with consolidated revenue up 7.2% and EBITDA margins at 50.6%.
Anthem Biosciences Limited (NSE: ANTHEM) has announced robust financial results for the second quarter and half year of FY27, showcasing significant growth and margin expansion. Consolidated revenue from operations for the quarter stood at ₹5,940 Mn, up 7.9% YoY, while EBITDA was ₹3,304 Mn, marking a 24.1% increase. The company’s profit after tax (PAT) for Q2FY27 was ₹2,115 Mn, reflecting a 21.9% rise compared to the same period last year.
Half-Year Financial Highlights
For the first half of FY27, Anthem Biosciences Limited reported consolidated revenue from operations of ₹10,123 Mn, a decrease of 7.2% YoY. However, the company’s EBITDA for H1 FY27 was ₹5,059 Mn, with margins at 46.2%. The PAT for H1 FY27 was ₹3,314 Mn, showing a 7.2% increase compared to H1 FY26.
Margin and Cost Efficiency
Anthem Biosciences Limited has demonstrated strong performance in maintaining and expanding its EBITDA and PAT margins. The company’s ability to sustain growth is attributed to strict discipline around cost efficiencies, yield optimization, and workforce productivity. This has further solidified its industry-leading margins, positioning the company well to sustain this performance throughout the year.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Anthem Biosciences Limited
Anthem Biosciences Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.
Anthem posts a 5.8% three-month gain, but softens in the last few weeks. The PEG stands at 5.22 — severely stretched. Any earnings miss could trigger a sharp de-rating. Industry-leading margins of 28.7% reflect exceptional pricing power and operational efficiency. The stock gives back 9.5% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The business grows revenue at 26.2% and profits at 15.4%, with D/E of 0.00. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 5.22 premium is usually justified. Check Fundamentals of Anthem Biosciences Limited.
ANTHEM
Anthem Biosciences Limited (NSE: ANTHEM) breaks out, gains 5% intraday
Anthem Biosciences Limited (NSE: ANTHEM) stock cleared its 6M resistance trendline and is up 5% intraday at ₹896.8.
Anthem Biosciences Limited (ANTHEM) breaks out with a +5% gain today, clearing its 6-month resistance trendline. This move is driven by strong technical momentum, with the stock now trading 12.0% above the resistance level of ₹789. Anthem Biosciences, a key player in the biotechnology sector, is showing robust performance despite the extended nature of this move, which is 10% above the 50-DMA.
Technical setup — trendlines & DMA
The current trendline structure for Anthem Biosciences shows a 6-month support floor at ₹765.7, which is 14.62% below today’s price. The resistance trendline, previously at ₹789.08, has been decisively broken, indicating a strong upward momentum. The 50-DMA at ₹776.6 is above the 200-DMA at ₹705.7, signaling a bullish trend. The stock is currently trading in the upper third of its 52-week range, suggesting that much of the recent move is already priced in, though it remains near yearly highs.
Snapshot: ₹896.80 on 2026-08-11 (chart frozen at publication)
Fundamentals & business context
With a PE of 84.5, Anthem Biosciences’ valuation appears stretched, especially when considering its 28.7% profit margin and a revenue CAGR of 26.2%. This suggests that the market may be pricing in future growth expectations, though the current valuation seems high relative to the company’s current earnings. Institutional ownership stands at 12.5%, indicating a cautious yet interested stance from smart money. There is no NSE catalyst today, making this move primarily technical in nature.
Algorithmic scorecard
The overall scorecard reflects a technically strong but fundamentally mixed picture. The strongest signals come from the company’s excellent revenue growth and very low debt levels, indicating solid financial health and consistent business performance. However, the weakest signals are the overvalued PEG ratio and negligible dividend yield, which pose risks of overpricing and lack of income generation for investors. These factors need careful consideration despite the strong technical performance.
Company outlook
Management provided forward-looking guidance indicating that Q1 FY27 will be the softest quarter, with growth expected from Q2 onwards. They anticipate a normalization of the tax rate to about 25% and expect to maintain margins due to order book visibility and cost efficiencies. Additionally, ESOP costs are expected to decline from FY28. On the investment front, Unit 4 is planned for completion by the end of FY28, adding significant capacity. The targeted capex for FY27 is set at approximately Rs. 700 crores, reflecting continued investment in growth and capacity expansion.
Get all details on ANTHEM — P&L, peers, shareholding and more on TradeAlone.
ANTHEM
Anthem Biosciences Limited (NSE: ANTHEM) breaks below support, falls 5%
Anthem Biosciences Limited (NSE: ANTHEM) stock price falls 5% intraday to ₹746.1, breaking below support in a sectoral breakdown..
Anthem Biosciences Limited (ANTHEM) breaks below support, falling -5% to ₹746.1 on the NSE on 22 Jul 2026, backed by the recent investor presentation announcement on July 21, 2026. The stock’s decline today appears to be a reaction to the presentation, where the company discussed its strategic direction and financial performance amidst market uncertainties. This move is somewhat isolated to Anthem, as the broader biotech sector remains stable.
Technical setup — trendlines & DMA
From a technical perspective, Anthem Biosciences is currently in a breakdown phase, having fallen below its 6-month support trendline of ₹757.3. The stock is now trading 1.50% below this support level, indicating a potential shift in short-term momentum. Resistance remains at ₹810.61, which is 8.65% above the current price. The 50-day moving average (DMA) at ₹770.8 is above the 200-DMA at ₹701.3, suggesting a bullish underlying trend, though the stock is currently trading below both moving averages. In terms of its 52-week range, the stock is positioned in the middle third, 57% above the 52-week low and 14.6% below the 52-week high, indicating that a significant portion of its potential upside may already be priced in.
Snapshot: ₹746.10 on 2026-07-22 (chart frozen at publication)
Fundamentals & business context
On the fundamental front, Anthem Biosciences presents a mixed picture. With a PE ratio of 74.6 and profit margins of 27.8%, the stock appears richly valued relative to its earnings. However, its revenue CAGR of 26.2% over the past five years suggests strong growth potential. The company’s institutional holding of 12.3% indicates a level of confidence from sophisticated investors, though it is not overwhelmingly high. There was no specific NSE catalyst today beyond the investor presentation, which may have contributed to the stock’s decline as investors digested the information provided.
Algorithmic scorecard
The overall algorithmic scorecard for Anthem Biosciences reflects a technically strong but fundamentally weaker profile. Two of the strongest signals are the company’s excellent revenue CAGR of 26.2%, indicating robust growth, and its very low debt levels with a D/E ratio of 0.00, showcasing strong financial health. On the flip side, the stock’s overvaluation with a PEG ratio of 4.84 and negligible dividend yield of 0.26% are significant weaknesses. The overvaluation suggests that the stock may be pricing in future growth that has not yet materialized, while the low dividend yield offers little income to investors, making the stock less attractive from an income perspective.
Company outlook
Management’s forward guidance for Anthem Biosciences is optimistic, with aspirations to maintain a historical growth rate of upwards of 20%. They anticipate growth in the GLP-1 market as an alternative to Chinese imports and aim for a 20% growth in the specialty ingredients business. The ramp-up of newly launched commercial molecules is expected over the next two to three years. Additionally, the company is open to acquisitions in India and abroad if they align with their strategic goals. This outlook suggests a focus on both organic growth and strategic acquisitions to drive future performance.
Get all details on ANTHEM — P&L, peers, shareholding and more on TradeAlone.
-
Financial Services3 days agoSammaan Capital Limited (sammaancap) Q2 FY27: Disbursements Rise 62% Qoq and PAT Grows 28%
-
Capital Markets3 days agoMaster Trust Limited (mastertr): Mastercapitalservices Raises ₹75 Cr Through Ncds
-
Consumer Cyclical3 days agoSenco Gold Limited (senco) Investor Presentation Q2 & H1 FY27 Highlights
-
Healthcare3 days agoZydus Lifesciences Limited (zyduslife) Inspection by USFDA Concludes at Liqmeds, UK
-
MAXESTATES2 days agoMax Estates Limited (maxestates) Reimagines Luxury Living Through ‘the Bungalows’
-
Financial Services3 days agoSammaan Capital Limited (sammaancap) Q2fy27 Investor Presentation: Strong Growth and Expansion
-
Consumer Cyclical3 days agoSenco Gold Limited (senco) Q2 FY27: Revenue Growth of 34%, Retail Expansion Adds 14 Showrooms
-
Basic Materials3 days agoGalaxy Surfactants Limited (galaxysurf) Signs Mou with LG Electronics for Sustainable Cleaning Solutions
